Zhejiang Ausun Pharmaceutical is a leading pharmaceutical company specializing in the research, development, production, and sale of specialty raw materials and pharmaceutical intermediates. They also offer customized processing and research services. Their products are known for their complex chiral structures, high research difficulty, technological barriers, and unique production processes.

As a high-tech enterprise, they have been recognized as a provincial-level research and development center and a provincial-level enterprise research institute. The company has excellent research platforms such as academicians' workstations, postdoctoral workstations, and postdoctoral innovation practice bases, and maintains good research cooperation with numerous universities and research institutes. Zhejiang Ausun Pharmaceutical, listed on the Shanghai Stock Exchange under the ticker code 603229, was established in April 2010 and is located in the Taizhou Bay Economic and Technological Development Zone.

They have over 1,000 employees and a research and analysis team of over 300 professionals, including doctors and masters. With their expertise, they swiftly transform research achievements into industrial production to meet customer needs